Optikira is developing small molecule therapeutics to prevent cell death in pathologies caused by misfolded or unfolded proteins in disease like retinitis pigmentosa, diabetes and amyotrophic lateral sclerosis.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
In Feb 2017, OptiKira Receives $998,500 Grant from ALS Association to accelerate the discovery of new treatments for ALS.
In Sep 2015, OptiKira was awarded with two Small Business Technology Transfer (STTR) grants, from the National Eye Institute (NEI) and from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Additional funding is also provided by BioMotiv associated with The Harrington Project for Discovery & Development, a $250 Mn national initiative for advancing medicine centred at University Hospitals in Cleveland.